Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.38 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.38 |
| ▸ | MASP2 | O00187 | 3/20 | 0.38 |
| ▸ | REN | P00797 | 3/20 | 0.37 |
| ▸ | FURIN | P09958 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145528 | 1.00 | CTSS (0.41) | CTSSCTSKAAK1CACNA1BCYP3A4 | |
| SCHEMBL3141442 | 0.91 | REN (0.43) | REN | |
| SCHEMBL3141428 | 0.91 | REN (0.43) | REN | |
| SCHEMBL3141449 | 0.91 | REN (0.43) | REN | |
| SCHEMBL3141433 | 0.91 | REN (0.43) | REN | |
| SCHEMBL3148239 | 0.86 | MASP2 (0.43) | PSMB10PSMB2MASP2FURIN | |
| SCHEMBL1903263 | 0.86 | MASP2 (0.40) | PSMB10PSMB2MASP2FURIN | |
| SCHEMBL1432229 | 0.86 | MASP2 (0.43) | PSMB10PSMB2MASP2FURIN | |
| SCHEMBL1907930 | 0.86 | MASP2 (0.41) | PSMB10PSMB2MASP2FURIN | |
| SCHEMBL1432232 | 0.86 | MASP2 (0.43) | PSMB10PSMB2MASP2FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CTSS 3171/4885CTSK 2782/4885AAK1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.